Company / Free Cash Flow per Share
Celldex Therapeutics, Inc. Free Cash Flow per Share History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Free Cash Flow per Share
-$3.21
FY2025
5-year range
-$3.21 / -$1.33
FY2021-FY2025
Trend
-33.4%
vs FY2024
Sector context
#142 of 149
Health Care
What the data says
Among 149 Health Care companies, Celldex Therapeutics, Inc. is in the bottom 5% for free cash flow per share. Free Cash Flow per Share has fluctuated over the past 10 years, ranging from $-12.54 in FY2018 to $-0.84 in FY2017.
Based on SEC 10-K filings.
-3.21 in FY2025.
Declined from $-1.95 to $-3.21 over the past 2 years.
Health Care sector context is included.
Free Cash Flow per Share over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 5% in Health CareTop 95% of 149This company -$3.21 Sector average $5.00
▼
-164.2% below sector average
Key checks
Key Insights
- In FY2025, free cash flow per share decreased 33.4% year-over-year.
- Ranks #142 out of 149 companies in the Health Care sector.
- Peak free cash flow per share was recorded in FY2017.
- Lowest free cash flow per share in the period was in FY2018.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 0.40 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Free Cash Flow per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$3.21 | -33.4% |
| FY2024 | -$2.41 | -23.2% |
| FY2023 | -$1.95 | +12.7% |
| FY2022 | -$2.24 | -68.1% |
| FY2021 | -$1.33 | -25.6% |
| FY2020 | -$1.06 | +61.9% |
| FY2019 | -$2.78 | +77.8% |
| FY2018 | -$12.54 | -1385.5% |
| FY2017 | -$0.84 | +12.1% |
| FY2016 | -$0.96 | +8.6% |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026